Veracyte, Inc. (VCYT:NASDAQ) closed at $47.93 on October 23, 2026, up 4.11% on the day. The stock trades 21.3% below its 52-week high of $60.91 and 62.7% above its 52-week low of $29.46. Over the past year, it gained 30.5%. Veracyte, Inc. is part of the Health Care sector (Medical Specialities).
In 252 trading sessions since October 23, 2025, VCYT closed higher on 115 days (46%). Its best day was November 5, 2025 (+27.46%) and its worst was July 31, 2026 (-22.52%). The stock moved 10% or more in a single session 4 times. It opened at least 5% above the previous day's high 3 times.
Veracyte, Inc. operates as a molecular diagnostics company in the United States. The company uses genomic technology to resolve diagnostic ambiguity. It offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients. The company's products also include Percepta Bronchial Genomic Classifier solution for use in lung cancer screening and diagnosis; and Envisia Genomic Classifier solution for idiopathic pulmonary fibrosis. It sells its products through its product specialists, institutional channel managers, account managers, and clinical science specialists. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Find more stocks like VCYT with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.